Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
DiaMedica Therapeutics Inc(DMAC)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for DMAC
10/08/2026: DMAC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
DiaMedica Therapeutics is a clinical-stage biotechnology company focused on developing DM199, a therapy for chronic kidney disease and potentially acute ischemic stroke. Its strength lies in its specialized focus on the kallikrein-kinin system, which offers a unique mechanism for treating underserved conditions. The primary investment story rests on the successful clinical development and regulatory approval of DM199. However, the company faces significant risks, including binary clinical outcomes, reliance on a single lead asset, and intense competition from much larger, better-funded pharmaceutical firms. It is best suited for speculative investors who monitor clinical trial readouts closely as the primary driver of value.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high growth potential linked to clinical breakthroughs, but lacks current commercial performance. |
| Momentum investor | Mixed fit | Momentum is often driven by clinical trial updates, making it a conditional fit based on positive news flow. |
| Value investor | Weak fit | Without earnings or cash flow, the stock does not meet traditional value investing criteria. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses on capital appreciation. |
| Low-risk investor | Weak fit | The binary risks associated with clinical development make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage stocks frequently experience sharp price moves based on trial results and regulatory updates. |
| Valuation risk | High | Valuations are speculative and sensitive to the probability of success for lead candidates. |
| Competition risk (large pharma) | High | Large incumbents can out-spend and out-maneuver smaller players in clinical testing and market access. |
| Business quality | Medium / high | The business relies entirely on the quality and success of its proprietary intellectual property. |
| Dividend income | Low / none | There is no income component to the investment. |
| Execution risk | High | Successful drug development requires complex, error-free clinical execution and regulatory navigation. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 10.11% | Avg. Invested days 41 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/08/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 430.87M USD | Price to earnings Ratio - | 1Y Target Price 15.5 |
Price to earnings Ratio - | 1Y Target Price 15.5 | ||
Volume (30-day avg) 201.9K shares | Beta 0.91 | 52 Weeks Range 5.25 - 10.42 | Updated Date 10/07/2026 |
52 Weeks Range 5.25 - 10.42 | Updated Date 10/07/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.72 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development | Development and potential future commercialization of DM199. | The company currently makes no money; revenue depends entirely on the future success of its drug development programs. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 364.36M | Price to Sales(TTM) 66.68 |
Enterprise Value 364.36M | Price to Sales(TTM) 66.68 | ||
Enterprise Value to Revenue 57.48 | Enterprise Value to EBITDA -0.96 | Shares Outstanding 53.93M | Shares Floating 25.30M |
Shares Outstanding 53.93M | Shares Floating 25.30M | ||
Percent Insiders 27.83 | Percent Institutions 40.91 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About DiaMedica Therapeutics Inc
Exchange NASDAQ | Headquarters Minneapolis, MN, United States | ||
IPO Launch date 2008-01-04 | President, CEO & Director Mr. Dietrich John Pauls MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 35 | Website https://www.diamedica.com |
Full time employees 35 | Website https://www.diamedica.com | ||
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.